EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal ...

“Individuals living with rare diseases, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis, often have limited access to life-enh ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...

Soliris contributed $2.58 billion in global revenues to AZ last year, a 14% drop on the prior year, of which just over $1.4 ...

Teva Pharma (TEVA) stock gains as the company and Samsung Bioepis launch Epysqli, a biosimilar to AstraZeneca's (AZN) rare ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.

Epysqli is used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia ...

Israel-based Teva Pharmaceuticals industries (NYSE: TEVA) today revealed two important updates reflecting its commitment to ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for ...